Bluejay Diagnostics announces SYMON-II sepsis study enrollment completion

• Bluejay Diagnostics posted a press release on SYMON-II, confirming completion of enrollment in its multicenter clinical validation study.
• Target of 750 sepsis patients met ahead of schedule; study evaluates Symphony IL-6 test for 28-day all-cause mortality risk.
• Preliminary enrolled-population data indicate about a 17% 28-day mortality rate; results expected after data cleaning and analysis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluejay Diagnostics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210630PRIMZONEFULLFEED9764992) on July 21, 2026, and is solely responsible for the information contained therein.